HLN — Haleon plc

Summary of Haleon (HLN) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Organic Sales Growth: 3% for FY 2025, below expectations due to a weak cold and flu season, particularly in the U.S.
• Market Performance: U.S. sales declined by approximately 0.5%, while APAC and EMEA/LatAm reported mid-single-digit growth.
• Gross Margin Improvement: Achieved a 220 basis points increase, contributing to high single-digit operating growth at constant currency.
• A&P and R&D Investment: Increased by over 7% year-on-year, focusing on Oral Health and emerging markets.

2. Strategic Updates and Business Highlights

• New Organizational Structure: Introduced a Chief Growth Officer and Chief Transformation Officer, along with a streamlined operating model consisting of six units to enhance agility and growth potential.
• Focus on Oral Health: Strong performance in Oral Health, particularly with brands like Sensodyne and Parodontax, which are expected to drive future growth.
• Emerging Markets: Continued strong performance, particularly in India and China, with significant growth driven by volume mix and penetration strategies.

3. Forward Guidance and Outlook

• 2026 Organic Sales Growth Guidance: Projected between 3% to 5%, with expectations for a return to growth in the U.S. market.
• Medium-Term Ambition: Reiterated target of 4% to 6% organic sales growth, contingent on improved market conditions and effective execution of strategic initiatives.

4. Bad News, Challenges, or Points of Concern

• Cold and Flu Category Impact: Continued underperformance in the cold and flu segment, which has affected overall sales and market share.
• U.S. Market Challenges: The U.S. market remains uncertain, with cautious consumer behavior and inventory management issues persisting.
• Volume Growth Concerns: Historical volume growth has been low (around 1%), raising questions about the ability to achieve the desired growth rates without significant improvement in volume metrics.

5. Notable Q&A Insights

• Drivers of Future Growth: CEO Brian McNamara emphasized the importance of category growth, innovation, and improved commercial execution as key drivers for the anticipated recovery.
• Emerging Markets Performance: CFO Dawn Allen highlighted strong growth in Asia Pacific, particularly in India, while noting challenges in Latin America due to macroeconomic pressures.
• Shelf Space and Retail Dynamics: The importance of securing shelf space was discussed, particularly in relation to the cold and flu business, which is critical for maintaining competitive positioning.
• A&P Effectiveness: There was a focus on improving the efficiency of A&P spending, with a significant portion allocated to Oral Health, which has shown strong ROI.

Overall, while Haleon demonstrated resilience in certain segments, particularly Oral Health and emerging markets, it faces significant challenges in the U.S. market and cold and flu categories, necessitating strategic adjustments and continued focus on innovation and operational efficiency.